Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta
NCT07557446Phase 2Recruiting
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AGA2115 in osteogenesis imperfecta (OI), sponsored by Angitia Biopharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
AGA2115
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT07557446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557446.